PB
Paradigm Biocapital Advisors LP disclosed a 5.1% stake in SYRE
Paradigm Biocapital Advisors LP reported owning 5.1% of Spyre Therapeutics, Inc. (SYRE) (4,457,450 shares) in a Schedule 13G filed Oct 1, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Oct 1, 2026
- Source
- Schedule 13G